Skip to main
CVSA

CVSA Stock Forecast & Price Target

CVSA Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Covista is poised for success in the healthcare education sector, with a strong focus on meeting the growing demand for healthcare professionals and a shareholder-friendly approach. The company's potential for margin expansion and strong vision for becoming a key player in the healthcare industry make it an attractive investment, receiving an OUTPERFORM rating.

Bears say

Covista is facing challenges with their Chamberlain segment, which has underperformed with weaker new starts, leading to a decline in the company's valuation. The company's partnership with Sallie Mae to finance additional loans for students beyond the new caps imposed by the Education Department could potentially limit future enrollment and pricing power. Additionally, the company's plan to expand through new Chamberlain campuses and potential M&A activity may be hindered by high valuation expectations for nursing schools and regulatory restrictions. Despite the company's growth in the Walden segment and opportunities in the medical and veterinary schools, Covista's stock valuation remains at a discount to its peers, indicating continued skepticism from investors.

CVSA has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Adtalem Global Education Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Adtalem Global Education Inc (CVSA) Forecast

Analysts have given CVSA a Buy based on their latest research and market trends.

According to 2 analysts, CVSA has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $150, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $150, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Adtalem Global Education Inc (CVSA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.